Cadrenal Therapeutics Inc... (CVKD)
16.28
0.10 (0.62%)
At close: Apr 22, 2025, 3:59 PM
16.10
-1.13%
Pre-market: Apr 23, 2025, 04:11 AM EDT
0.62% (1D)
| Bid | 15.31 |
| Market Cap | 30.6M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.65M |
| EPS (ttm) | -8.73 |
| PE Ratio (ttm) | -1.86 |
| Forward PE | -7.33 |
| Analyst | Strong Buy |
| Ask | 18 |
| Volume | 15,189 |
| Avg. Volume (20D) | 35,462 |
| Open | 16.65 |
| Previous Close | 16.18 |
| Day's Range | 15.85 - 16.71 |
| 52-Week Range | 5.70 - 22.90 |
| Beta | 1.46 |
About CVKD
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida....
Industry Biotechnology
Sector Healthcare
IPO Date Jan 20, 2023
Employees 4
Stock Exchange NASDAQ
Ticker Symbol CVKD
Website https://www.cadrenal.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CVKD stock is "Strong Buy." The 12-month stock price forecast is $32, which is an increase of 96.56% from the latest price.
Stock Forecasts6 months ago
+17.97%
Cadrenal Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
